Daily Peptide Briefing

GLP-1 receptor agonist use and mental health outcomes in adolescents with obesity: a retrospective review.

Journal of pediatric endocrinology & metabolism : JPEM

GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide)/GLP-1 Receptor Agonists for Antipsychotic-Induced Weight Gain: A Narrative Review.

Cureus

Oral Adverse Effects of Semaglutide Therapy: A Narrative Review.

Journal of International Society of Preventive & Community Dentistry

Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study.

Journal of asthma and allergy

Weight regain following discontinuation of glucagon-like peptide-1 receptor agonists in adults who are overweight or obese: a systematic review and meta-analysis.

PeerJ

Diabetes, Adiposity, and Functional Phenotypes in HFpEF: A Systematic Review of Recent Treatment-Response Evidence.

Cureus

Oral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.

Frontiers in pharmacology

Case Report: Tirzepatide improves glycemic control in Rabson-Mendenhall syndrome.

Frontiers in endocrinology

The "Peptide Revolution" is here, but most people are treating it like the Wild West. We see it every day.. Someone sees an infographic about BPC-157 or MOTS-c, orders a "research chemical" from a questionable website, and hopes for the best. That isn’t modern medicine. https://t.co/e9uU1dYS6H

For almost every peptide people run at home, subcutaneous is the right route and intramuscular offers no advantage worth the downside. Subcutaneous means into the fat layer just under the skin, using a short insulin needle at a shallow angle. It is easy to do yourself, it has a

According to the FDA, the agency has now received 990 adverse-event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA's updated GLP-1 guidance + where it sees problems: > Retatrutide and cagrilintide cannot be used in

The image details an informational chart about Foundayo (orforglipron), which is a non-peptide, small-molecule GLP-1 receptor agonist. It highlights its clinical applications, dosing regimens, safety profile, and direct comparison to oral semaglutide. Key Clinical Information https://t.co/N3fJrnmS0p

15 products. One growing catalog. Including: BPC-157, MOTS-c, Retatrutide, Semaglutide, Sermorelin, GHK-Cu, Tesamorelin, Tirzepatide Benefits span metabolism, recovery, skin biology, and cellular energy. See what we got ↓ https://t.co/XaXIOg0NQy

DelveInsight expects the obesity treatment market to grow rapidly over the next decade as competition expands beyond $NVO and $LLY The obesity market across the U.S., Germany, France, Italy, Spain, the UK and Japan was worth approximately $16 billion in 2025 and is projected

1/ Everyone's injecting BPC-157 because "the FDA finally admitted it's safe." The FDA admitted no such thing. Here's the actual paper trail, with dates. 🧵 2/ Feb 27, 2026: HHS Secretary Kennedy announced the peptide policy shift on Joe Rogan (ep #2461). Not the Federal

This Week in Longevity: What’s Real, What’s Hype Everyone wants the pill that makes us live longer. But the real question is not whether something extends the life of a mouse, changes a blood test, or produces a beautiful headline. The question is: Will it help human beings https://t.co/jzeohGA1Ui